Amneal Pharmaceuticals, INC Form 4 insider transactions

Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, Inc., sold 146,403 shares of common stock on August 12, 2026 for $17.51 per share.

Tushar Bhikhubhai Patel, a 10% owner of Amneal Pharmaceuticals, Inc., received 12,763,469 shares of common stock on August 10, 2026.

Chintu Patel, Co-CEO and a Director of Amneal Pharmaceuticals, Inc., received 6,381,734 shares of common stock on August 10, 2026.

Gautam Patel, a Director of Amneal Pharmaceuticals, Inc., received 283,632 shares of common stock on August 10, 2026.

Chirag K. Patel, President & Co-CEO and a Director of Amneal Pharmaceuticals, Inc., received 6,381,734 shares of common stock on August 10, 2026.

Amneal Pharmaceuticals Director Deborah M. Autor reported a sale of 34,819 shares of Class A Common Stock on May 11, 2026, for a weighted average price of $12.94 per share.

Director J. Kevin Buchi acquired 34,819 shares of Amneal Pharmaceuticals via restricted stock unit vesting and received a new grant of 19,824 units.

Director Deborah M. Autor acquired 34,819 shares of Amneal Pharmaceuticals through the vesting of restricted stock units.

Director Jeffrey P. George acquired 34,819 shares of Amneal Pharmaceuticals through the vesting of restricted stock units.

Director Gautam Patel acquired 34,819 shares of Amneal Pharmaceuticals via restricted stock unit vesting and was granted 19,824 new units.

Director John Kiely acquired 34,819 shares of Amneal Pharmaceuticals through the vesting of restricted stock units.

Director Ted Nark acquired 34,819 shares of Amneal Pharmaceuticals through the vesting of restricted stock units and was granted 19,824 new units.

Director Paul M. Meister acquired 48,747 shares of Amneal Pharmaceuticals through the vesting of restricted stock units.

Amneal Pharmaceuticals director Shlomo Yanai acquired 34,819 shares through the vesting of restricted stock units and was granted 19,824 new units.

Amneal Pharmaceuticals amends a filing to clarify Co-CEO Chintu Patel's equity award consists entirely of performance-based restricted stock units.

Amneal Pharmaceuticals, Inc. filed an amended Form 4 to correct the classification of a significant equity grant to President and Co-CEO Chirag K. Patel, clarifying it as 100% performance-based restricted stock units.

Amneal Pharmaceuticals Co-CEO Chintu Patel increased his direct beneficial ownership of Class A Common Stock through RSU and performance-based RSU vestings, despite shares withheld for tax obligations.

Amneal Pharmaceuticals' President and Co-CEO, Chirag K. Patel, reported the vesting of over 886,000 shares of Class A Common Stock, including performance-based units that achieved a 200% vesting threshold.

Amneal Pharmaceuticals' EVP and Chief Legal Officer, Jason B. Daly, reported the vesting of restricted stock units and subsequent sales to cover tax obligations.

Amneal Pharmaceuticals' EVP & CFO Tasos Konidaris increased his direct ownership of Class A Common Stock through the vesting of restricted stock units, including performance-based units that achieved a 200% vesting threshold.

Amneal Pharmaceuticals Executive Vice President Andrew S. Boyer acquired over 500,000 shares through restricted stock unit vesting, including performance-based units that vested at 200% of target.

Amneal Pharmaceuticals Executive Vice President Nikita Shah acquired shares through RSU and PBRSU vesting and subsequently sold a portion to cover tax liabilities.

Amneal Pharmaceuticals' Executive Vice President, Andrew S. Boyer, received grants of restricted stock units and performance-based restricted stock units.

Amneal Pharmaceuticals Director Ted C. Nark sold 50,000 shares of Class A Common Stock for approximately $11.72 per share, as reported in a recent SEC Form 4 filing.

Amneal Pharmaceuticals Executive Vice President Nikita Shah exercised stock options and subsequently sold a portion of Class A Common Stock.

Amneal Pharmaceuticals Director John Kiely filed a Form 4 disclosing a future planned sale of 32,000 Class A Common Stock shares under a 10b5-1 plan.

Amneal Pharmaceuticals Executive Vice President Nikita Shah sold a total of 120,832 shares of Class A Common Stock in two transactions in August 2025.

Amneal Pharmaceuticals Executive Vice President Andrew S. Boyer exercised stock options and subsequently sold a portion of his Class A Common Stock.

Amneal Pharmaceuticals' Executive Vice President, Nikita Shah, sold 71,694 shares of Class A Common Stock for approximately $665,937 in a pre-planned transaction.

Amneal Pharmaceuticals' CFO, Tasos Konidaris, sold nearly 500,000 shares of Class A Common Stock over three days in August 2025, reducing his direct holdings.